Cardea Bio: high-speed biosensing using graphene
San Diego company’s technology allows molecular binding events to be monitored electrically, in real time
Cardea Bio has created graphene-based biosensors that enable any molecular binding event to be monitored more directly and with better time resolution than is possible with traditional measurement platforms. The company is commercializing the sensors using a business model normally employed by semiconductor manufacturers, and announced a collaboration in January with Siemens Healthineers to use the tech to develop a SARS-CoV-2 immunoassay.
Cardea Bio Inc. was co-founded by Michael Heltzen, who, as director of the Danish bioinformatics company CLC bio, had grown frustrated with the historical reliance of life science companies on optical methods of detecting biomolecules such as proteins. He wanted to work with streams of data instead of datasets, he told BioCentury. ...